Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?

Tenenbaum A, Boyko V, Fisman EZ, Goldenberg I, Adler Y, Feinberg MS, Motro M, Tanne D, Shemesh J, Schwammenthal E, Behar S.

Cardiovasc Diabetol. 2008 Jun 19;7:18.

PMID: 18565233 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.

Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S.

Circulation. 2004 May 11;109(18):2197-202. Epub 2004 May 3.

PMID: 15123532 [PubMed - indexed for MEDLINE]

Related Articles

Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.

Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S.

Arch Intern Med. 2006 Apr 10;166(7):737-41.

PMID: 16606809 [PubMed - indexed for MEDLINE]

Related Articles

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

Tenenbaum A, Motro M, Fisman EZ.

Cardiovasc Diabetol. 2005 Sep 16;4:14. Review.

PMID: 16168052 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.

Kohno H, Suzuki R, Sugie S, Tanaka T.

BMC Cancer. 2005 May 16;5:46.

PMID: 15892897 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A.

Eur Heart J. 1996 Dec;17 Suppl F:37-42. Review.

PMID: 8960446 [PubMed - indexed for MEDLINE]

Related Articles

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.

Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S.

Arch Intern Med. 2005 May 23;165(10):1154-60.

PMID: 15911729 [PubMed - indexed for MEDLINE]

Related Articles

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.

Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U.

Lancet. 1996 Mar 30;347(9005):849-53.

PMID: 8622389 [PubMed - indexed for MEDLINE]

Related Articles

High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.

Arcavi L, Behar S, Caspi A, Reshef N, Boyko V, Knobler H.

Am Heart J. 2004 Feb;147(2):239-45.

PMID: 14760320 [PubMed - indexed for MEDLINE]

Related Articles

Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes.

Tenenbaum H, Behar S, Boyko V, Adler Y, Fisman EZ, Tanne D, Lapidot M, Schwammenthal E, Feinberg M, Matas Z, Motro M, Tenenbaum A.

Atherosclerosis. 2007 Sep;194(1):265-71. Epub 2006 Sep 12.

PMID: 16970952 [PubMed - indexed for MEDLINE]

Related Articles

Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level.

Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, Fisman EZ, Tanne D, Matas Z, Hibuse T, Fujita K, Nishizawa H, Adler Y, Motro M, Kihara S, Shimomura I, Behar S, Funahashi T.

Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):635-41. Epub 2006 Dec 28.

PMID: 17194889 [PubMed - indexed for MEDLINE]

Related Articles

Long-term diuretic therapy in patients with coronary disease: increased colon cancer-related mortality over a 5-year follow-up.

Tenenbaum A, Grossman E, Fisman EZ, Adler Y, Boyko V, Jonas M, Behar S, Motro M, Reicher-Reiss H.

J Hum Hypertens. 2001 Jun;15(6):373-9.

PMID: 11439311 [PubMed - indexed for MEDLINE]

Related Articles

Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.

Goldenberg I, Benderly M, Goldbourt U; BIP Study Group.

J Am Coll Cardiol. 2008 Jan 29;51(4):459-65.

PMID: 18222357 [PubMed - indexed for MEDLINE]

Related Articles

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.

Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD.

Diabetes Care. 1998 Apr;21(4):641-8.

PMID: 9571357 [PubMed - indexed for MEDLINE]

Related Articles

Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.

Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S.

Eur Heart J. 2005 Oct;26(19):2032-8. Epub 2005 May 4.

PMID: 15872029 [PubMed - indexed for MEDLINE]

Related Articles

Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor.

Tanne D, Koren-Morag N, Graff E, Goldbourt U.

Circulation. 2001 Dec 11;104(24):2892-7.

PMID: 11739302 [PubMed - indexed for MEDLINE]

Related Articles

Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.

Fruchart JC, Duriez P.

Drugs Today (Barc). 2006 Jan;42(1):39-64. Review.

PMID: 16511610 [PubMed - indexed for MEDLINE]

Related Articles

Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

de Faire U, Ericsson CG, Hamsten A, Nilsson J.

Drugs Exp Clin Res. 1995;21(3):105-24.

PMID: 7555614 [PubMed - indexed for MEDLINE]

Related Articles

C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease.

Haim M, Benderly M, Tanne D, Matas Z, Boyko V, Fisman EZ, Tenenbaum A, Zimmlichman R, Battler A, Goldbourt U, Behar S.

Am Heart J. 2007 Dec;154(6):1095-101. Epub 2007 Sep 27.

PMID: 18035081 [PubMed - indexed for MEDLINE]

Related Articles

Is hypoglycaemia a marker for increased long-term mortality risk in patients with coronary artery disease? An 8-year follow-up.

Fisman EZ, Motro M, Tenenbaum A, Leor J, Boyko V, Mandelzweig L, Sherer Y, Adler Y, Behar S.

Eur J Cardiovasc Prev Rehabil. 2004 Apr;11(2):135-43.

PMID: 15187817 [PubMed - indexed for MEDLINE]

Related Articles